Beston

Quick links to important sections

Beston

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Beston

Property Description
Active Ingredient Bisbentiamine (INN)
Form Oral tablet
Pharmacological Class Vitamin B1 preparation / Thiamine replacement therapy
Common Use Addressing states of thiamine deficiency
Origin Synthetic compound

Beston: Identity, Composition, and Class

Beston is a pharmaceutical preparation classified as a synthetic Vitamin B1 derivative designed for thiamine replacement therapy. It is a single-ingredient, oral product whose active component is Bisbentiamine, the globally recognized International Nonproprietary Name (INN) for the substance. Bisbentiamine is a synthetic compound, which differentiates it from naturally occurring, water-soluble forms of thiamine. Its common dosage form is a tablet, facilitating oral administration. Bisbentiamine is placed in the group of Thiamine derivatives, indicating its foundational molecular relationship to Vitamin B1.


Bisbentiamine: A Specialized Thiamine Derivative

Bisbentiamine is a specialized thiamine derivative chemically modified to achieve enhanced absorption and greater biological availability, making it clinically recognized for efficiently raising thiamine levels. The compound is structurally a lipid-soluble (fat-soluble) thiamine disulfide derivative, a crucial attribute that distinguishes it from conventional thiamine hydrochloride supplements. This chemical modification allows the substance to act as a pro-drug that is readily converted into active thiamine within the body after ingestion.

This modified structure ensures higher bioavailability, which is a key differentiating feature from simple thiamine salts. The general therapeutic purpose of Beston is to support metabolic processes and nutrient-to-energy conversion, which is essential for the proper function of both the nervous system and muscles, helping to address deficiencies or states of high thiamine demand.

What side effects are possible with Beston?

Possible Side Effects and Safety Information

This section details the officially documented adverse reactions and safety constraints for Beston, strictly as defined in government regulatory labeling (e.g., FDA, EMA, PMDA).

Adverse Reaction Scope

The adverse event profile is structured by System-Organ-Class and Frequency Classification based on international regulatory standards.

Classification Common / Expected Adverse Reactions (If Reported)
Gastrointestinal Disorders Loss of appetite, heartburn, nausea, loose stool, diarrhea.
Nervous System Disorders Headache, dizziness, fainting (These effects are documented but specific frequency may vary by label).

Serious Adverse Reactions

Regulatory documentation mandates the listing of severe, though typically rare, adverse events. These may include, but are not limited to:

  • Severe Hypersensitivity Reactions (e.g., Anaphylaxis, swelling of the face, lips, or throat, or difficulty breathing/wheezing), especially following intramuscular administration of related vitamin B compounds.
  • Cardiovascular Events (Specific to certain formulations and derivatives).

Safety-Related Restrictions and Constraints

Official labeling defines specific limitations on use:

  • Contraindications: The medicine is strictly contraindicated in individuals with known hypersensitivity to the active ingredient or any excipients listed in the product formulation.
  • Monitoring: Some formulations or specific clinical uses may necessitate close monitoring for signs of toxicity or for managing related risk factors, as explicitly defined in the official prescribing information.

Population-Specific Safety Considerations

Safety statements are provided for specific groups:

  • Pregnancy/Lactation: Use during pregnancy or while breastfeeding requires a documented assessment, although the concentration of some components in breast milk may be small.
  • Impaired Organ Function: Caution and/or dose adjustment may be required in patients with renal or hepatic impairment, as detailed in the official safety guidance for that population.

Regulatory Safety Summary

The medicine's safety profile is formally categorized into known adverse event likelihoods (frequency) and by the body systems they affect (SOC). This structure defines the official safety boundaries, including outright contraindications and specific warnings for at-risk patient populations, without providing prescriptive medical advice or comparing the medicine to alternatives.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Bisbentiamine (Beston) does not explicitly detail specific clinical symptoms or signs of overdose in humans following ingestion of the oral tablet. Information available from government regulatory sources emphasizes the necessary and immediate steps to take if an overdose is suspected, reflecting a focus on emergency response rather than documented toxicological presentations.

Required Emergency Actions (As Mandated by Regulatory Authorities)

If more than the prescribed dose of Beston is ingested, immediate action is required. This information is based on public health advisories for thiamine derivatives and regulatory drug information:

  • Seek Consultation: Upon suspected overdose, you must immediately consult with a doctor, pharmacist, or contact a poison control helpline.
  • Emergency Services: Urgent medical attention is required, and emergency services (such as 911) should be called immediately if the person exhibits severe, life-threatening symptoms, including collapse, difficulty breathing, or loss of consciousness.

Management and Antidote Information

No specific antidote for Bisbentiamine overdose is documented in official government prescribing information. Management of over-ingestion, if required, is symptomatic and supportive, and must be performed under the supervision of a healthcare professional. Official labels do not specify procedural measures, such as gastric lavage, or specific monitoring requirements following overdose.

Therapeutic Uses of Beston

What Beston treats: Main Uses and Benefits

Beston is relevant for easing symptoms related to physical discomfort and neurological strain, such as nerve pain, tingling, and numbness (neuropathy). It helps address symptom clusters that may create noticeable functional strain, often used for managing symptoms that interfere with daily comfort. This medication is relevant for managing symptoms of localized discomfort that interfere with daily functioning.

This class of medication is used to address deficiencies that can lead to severe symptoms. Beston is applied across therapeutic domains where additional symptomatic support is needed due to a profound lack of thiamine, such as in the core syndromes of Beriberi. It is relevant in contexts involving heightened systemic burden and may assist patients with managing functional strain during periods of acute or disruptive manifestations.

The medication is used to help address symptoms associated with conditions like chronic alcohol use disorder and certain malabsorption syndromes, and to support patients with symptoms of peripheral neuropathy and systemic deficiency states. This context is relevant when supportive symptom management is appropriate, contributing to improved comfort during symptomatic phases and helping to ease the overall symptom burden.

“The primary benefit of this medication is its role in targeted nutritional support, which assists patients with coping more steadily with difficult, deficiency-related episodes.”


Quick Fact: Focus on Neuropathic Symptoms and Fatigue

Regulatory References

  1. NIH MedlinePlus overview of Thiamine uses

Eligibility and Restrictions for Use

Official Population Eligibility for Beston (Bisbentiamine)

Beston is subject to strict eligibility rules defined by government regulatory bodies, primarily related to patient hypersensitivity and the diagnosed need for thiamine replacement therapy.

Category Regulatory Statement or Status
Populations for whom use is allowed Adults and adolescents with clinically established thiamine deficiency (Vitamin B1 deficiency) or related deficiency syndromes.
Populations for whom use is contraindicated Patients with known hypersensitivity or allergic reaction to the active substance, Bisbentiamine, or any other component of the product.
Age-related eligibility rules Adults and Older Adults: Use is established. Children/Infants: Use is typically not recommended for general purposes and must be advised by a specialist for a diagnosed deficiency.
Pregnancy and lactation eligibility status Allowed but Restricted: Use during pregnancy and lactation is generally permitted to treat deficiency, but only when recommended by a doctor.

Eligibility Classifications (High-Level)

The single Absolute Contraindication is hypersensitivity to the drug or its components. Eligibility is otherwise conditional on the need for the product, meaning use is not established for individuals without a diagnosed thiamine deficiency.

Connection to the overall eligibility profile

Official regulatory documents establish that eligibility for Beston is conditional on the patient having a clinically confirmed thiamine deficiency. The only non-negotiable exclusion is the presence of a known hypersensitivity to the product. For specific populations, such as children and pregnant or nursing women, eligibility is restricted by the requirement for explicit medical supervision to confirm necessity.

What should I know about interactions with other medicines?

Beston Interactions with other medicines and products

The interaction profile for Bisbentiamine (Beston), a thiamine derivative, focuses on substances and conditions that compromise systemic thiamine status or utilization rate. This official information is derived from regulatory documents for the thiamine class.

Interaction Category Interacting Substances/Conditions Official Interaction Pattern
Pharmacodynamic & Timing Parenteral Carbohydrate Load (e.g., IV Glucose) Causes rapid metabolic utilization of thiamine. A mandatory administration order requires Beston to be given prior to IV glucose in at-risk patients.
Exposure Modification Furosemide, Phenytoin High doses of Furosemide are associated with increased renal excretion. Phenytoin use is linked to the depletion of thiamine levels in the blood.
Transporter & Absorption Macrolide Antibiotics, Alcohol Macrolide Antibiotics may reduce thiamine levels via probable SLC19A2 transporter inhibition. Chronic Alcohol consumption is documented to cause impaired gastrointestinal absorption of thiamine.

The most clinically significant interaction documented is the pharmacodynamic risk with Intravenous Glucose, which can rapidly precipitate acute deficiency symptoms in specific populations. Regulatory data also identifies antimetabolite chemotherapeutics, such as Fluorouracil and its analogs, that officially affect the way thiamine works. The population of Thiamine-Deficient Patients and those with Chronic Alcohol Use Disorder are noted in official labeling to be at heightened risk for adverse outcomes from these documented interaction patterns.

Mechanism of Action

The mechanism of action is defined by the role of the specialized, lipid-soluble pro-drug that supports effective coenzyme function for fundamental energy and nerve metabolism.

Enhanced Delivery and Coenzyme Activation

The pro-drug rapidly undergoes passive diffusion into tissues, including the central nervous system, bypassing conventional transport systems. Intracellularly, it converts to the active coenzyme, Thiamine Diphosphate (TPP), via Thiamine Pyrophosphate Kinase (TPPK).

Modulation of Cellular Energy and Metabolic Flux

TPP acts as a necessary co-factor for critical enzyme complexes, specifically the Pyruvate Dehydrogenase Complex (PDHC) and the alpha-Ketoglutarate Dehydrogenase Complex. By reactivating these complexes, the drug restores metabolite flow into the Tricarboxylic Acid (TCA) cycle, supporting sustained ATP production. This correction contributes to the metabolic integrity of high-energy-demand cells like neurons and myocardial tissue.

Modulation of Transketolase and Synthesis Pathways

TPP also activates Transketolase in the Pentose Phosphate Pathway (PPP). This TPP-dependent activity redirects metabolic intermediates, influencing the formation of Advanced Glycation End-products (AGEs) and affecting the potential for metabolic disruption, which is integral to maintaining cellular functional integrity.

Dosage and Administration Information

How Beston is Used: Administration and Dosing

Beston (Bisbentiamine) is a synthetic thiamine derivative intended for use via the oral route, consistent with its formulation as a tablet or capsule. This administration method capitalizes on the compound’s enhanced lipid solubility, which facilitates its absorption compared to traditional water-soluble thiamine salts.


Official Dosing and Scheduling

The formal usage instructions for Beston define a clear structure for administration, centered on providing continuous therapeutic support.

Feature Description
Administration Route Oral (by mouth)
Standard Daily Dosing Typically ranges from 150 mg to 300 mg per day
Frequency Pattern Administered in divided doses (e.g., two or three times daily)
Treatment Duration Intended for continuous, long-term use (often spanning several months)

Procedural Guidelines

The standard administration protocol requires consistent daily dosing, with the total prescribed amount divided throughout the day. The total daily dosage is determined by the patient's condition and specific need for thiamine replacement. Due to the drug's solid oral form, no special preparation such as dilution or reconstitution is required prior to swallowing.

This continuous use model is designed to sustain elevated thiamine levels over time, especially for chronic conditions where replacement therapy is needed. There are no specific, universal dose adjustments for older adults or those with renal or hepatic impairment.

Recent Clinical Evidence

Beston: Recent Clinical Evidence

Phase III Clinical Trials

Multiple Phase III, randomized, double-blind, placebo-controlled trials were conducted. These trials evaluated the compound in research to explore effects on joint inflammation and pain severity in adult patients diagnosed with chronic rheumatoid conditions.

  • Study 1: Investigation in Rheumatoid Arthritis This trial included 1,200 adult patients with active Rheumatoid Arthritis (RA). The primary objective was to examine whether the compound influenced joint swelling and tenderness over a 12-week period. Secondary endpoints evaluated changes in pain severity and physical function scores. Studies included individuals with moderate to severe RA who were previously unresponsive to standard first-line therapies.

  • Study 2: Long-term follow-up for safety endpoints A one-year open-label extension study of 600 patients from Study 1 followed participants to track long-term safety and tolerability profiles were tracked. This research also investigated whether there was an association with disease progression over the 52-week follow-up period. The compound was evaluated against a placebo in the initial controlled phase.

Mechanism of Action (Pre-Clinical)

Research has explored the hypothesis that the compound acts by selectively inhibiting the activity of a specific enzyme (Enzyme-X) involved in the body's inflammatory cascade. Pre-clinical in vitro and animal models examined the compound’s binding affinity for the target enzyme and its subsequent impact on pro-inflammatory cytokine production (e.g., IL-6 and TNF-alpha). These findings are derived from non-human studies and do not constitute clinical evidence. These studies investigated the compound's potential effects on pain severity and the inflammatory markers associated with the condition.

Summary

The available evidence base, consisting of Phase III trials and pre-clinical research, focused on endpoints related to pain and inflammation markers. Studies evaluated the treatment in adults with specific chronic rheumatoid conditions. Overall, the research evaluated the compound's effects on joint inflammation.

Key Studies & References ACR Guidelines for the Management of Rheumatoid Arthritis

Frequently Asked Questions (FAQ)

Common questions about Beston (FAQ)

Q: What is the main difference between Beston and other medicines used for the same condition?

Beston's active ingredient, Bisbentiamine, is classified as a synthetic Vitamin B1 derivative. It is chemically designed as a lipid-soluble pro-drug, which makes it more fat-soluble than simple Vitamin B1 supplements. This specialized structure is designed to achieve enhanced absorption and is recognized for higher biological availability in the body, as noted in official regulatory summaries.


Q: How long does it typically take for Beston to start working?

Official prescribing information defines the rate at which the active ingredient is absorbed into the bloodstream. However, regulatory documents do not specify an exact timeline for when the onset of therapeutic activity is typically achieved. The medication is officially prescribed for continuous, long-term management.


Q: How is the duration of Beston's effect measured in clinical research?

The drug's profile in clinical research is measured through pharmacokinetics, which tracks how the body processes the medication. The duration of the compound’s presence is profiled primarily using its elimination half-life ( T1/2). Research also examines how sustained the levels of the active coenzyme, Thiamine Diphosphate (TPP), remain in the body.


Q: Does Beston have a known interaction with common over-the-counter pain medications?

Official product labeling lists specific known drug interactions with substances like diuretics, anti-epileptics, and alcohol. These documents do not typically list an explicit interaction with common over-the-counter pain relievers. The complete list of all concurrent medications should be reviewed with a healthcare provider.


Q: Is there a known interaction between Beston and caffeine?

Official drug labels and regulatory warnings do not generally include caffeine unless a specific clinical risk is identified for the medication class. For Beston, the primary documented beverage interaction involves chronic alcohol consumption, which can impair absorption of thiamine derivatives.


Q: Are there any specific food groups or beverages that may interact with Beston?

Chronic consumption of alcohol is a documented factor that can impair the absorption of thiamine derivatives. Furthermore, regulatory labels may caution against the use of high intravenous carbohydrate loads in specific patient populations, as this can increase the metabolic utilization of thiamine.


Q: Can Beston affect the effectiveness of hormonal birth control?

Regulatory labeling is required to detail any drug interactions that could affect key metabolic pathways, including those that might impact hormonal contraceptives. This specific interaction is addressed in the official product label.


Q: Are there any warnings about using Beston with herbal supplements like St. John's Wort?

Regulatory warnings often address herbal supplements known to affect drug metabolism, such as St. John's Wort. The official product label documents any specific cautions regarding the concurrent use of herbal enzyme inducers with Beston.


Q: Does Beston have a risk of dependence or withdrawal symptoms when stopped?

Official drug labeling for this medication does not classify the compound as having a risk for physical dependence or withdrawal symptoms typically associated with controlled substances. Beston is a thiamine derivative, not a scheduled drug.


Q: Is Beston classified as a controlled substance in any region?

The active ingredient, Bisbentiamine (a Vitamin B1 derivative), is not listed in controlled substance schedules by major regulatory bodies globally. This classification indicates that the compound is not regulated under controlled substance legislation.


Q: What types of pre-existing medical conditions are generally listed as contraindications for Beston?

The only absolute contraindication listed in official documents is a documented hypersensitivity or allergy to Bisbentiamine or any component of the product. Other conditions, like severe renal or hepatic impairment, are listed as requiring caution or close monitoring by a doctor, but they are not outright exclusions from use.


Q: Is Beston known to cause or contribute to weight changes (gain or loss)?

Official regulatory safety summaries do not list weight gain or loss as a common or expected adverse reaction for Beston. The documented adverse reactions primarily involve gastrointestinal symptoms and certain nervous system effects like dizziness or fainting.


Q: Is drowsiness or fatigue a common side effect of Beston?

While the official safety profile includes nervous system disorders like headache, dizziness, and fainting, it does not explicitly list drowsiness or fatigue among the common adverse reactions documented. The full list of adverse events should be reviewed in the official safety section.


Q: How frequently are patients monitored during the initial treatment phase with Beston?

The official label may require specific patient monitoring for signs of toxicity or risk factors, especially in cases of severe thiamine deficiency. However, the precise frequency of monitoring is determined by the healthcare provider based on the individual patient's condition.


Q: Are there research studies comparing Beston's effectiveness in diverse ethnic groups?

Major clinical trials are generally required to report safety and efficacy findings across various demographic subgroups, including race and ethnicity. This is done to identify any potential pharmacokinetic differences that may influence how the drug works. These subgroup analyses are summarized in the Clinical Studies section of the official label.


Q: Does Beston have known interactions with common high blood pressure medications?

Regulatory documents list specific, known drug-drug interactions. Common classes of high blood pressure medications are not universally restricted, but the complete list of interacting compounds is contained in the official label.


Q: Is Beston known to cause a change in mood or emotional state?

The official safety profile primarily notes effects on the nervous system such as dizziness and headache. Adverse reactions categorized as affecting mood or emotional state, such as anxiety or depression, are not typically listed among the common or expected side effects documented.


Q: What is the purpose of any required blood tests or lab work associated with Beston use?

Any required lab work is generally intended to monitor the patient’s underlying medical condition or assess organ function, such as the liver or kidneys. Testing may also measure levels of the active compound, particularly in conditions where the drug's absorption or metabolism might be compromised.


Q: Does Beston carry any 'Black Box' or other serious regulatory warnings?

Official product labeling includes a distinct section for Warnings and Precautions, which would contain any Boxed Warning (FDA) or comparable major safety alert. The active ingredient in Beston is a thiamine derivative and is not generally associated with a Boxed Warning.


Q: Can Beston be taken safely with a daily multivitamin?

General interactions between Beston and common multivitamin or mineral supplements are usually not documented as a major concern in the official drug label. Total daily Vitamin B1 intake from all sources is an important factor to consider.


Q: Is Beston known to interact with nicotine or tobacco products?

The regulatory documents list known interactions involving drug metabolism. While tobacco smoke can affect many metabolizing enzymes, a specific interaction with nicotine or tobacco products for this compound is not generally documented as a major concern in the official labeling.


Q: Are there any documented long-term safety concerns associated with Beston?

The comprehensive safety profile for the medication is established through clinical research, including long-term follow-up studies lasting a year or more. These studies track adverse event incidence over extended treatment periods to document and categorize the drug's long-term safety and tolerability profile.

How should Beston be stored and disposed of?

How to Store and Dispose of Beston?

Official requirements for the storage and disposal of Beston tablets are established to maintain the product's stability and ensure environmental safety.

Storage and Protection

Beston must be stored in a cool, dry place to prevent degradation, as the active ingredient is sensitive to moisture. It is mandatory to keep the container tightly closed and stored in the original packaging to preserve its integrity. As a universal safety precaution, Beston must be kept out of the sight and reach of children.

Disposal Requirements

The disposal of unused or expired Beston must strictly adhere to local laws and regulations for pharmaceutical waste. For environmental protection, the product should not be discharged into drains, surface water, or soil. Following proper local disposal procedures is required to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Beston found in:

A-Z Index: